Scancell to Present Promising Phase 2 Melanoma Vaccine Data at AACR 2025

Scancell Holdings ( (GB:SCLP) ) has issued an announcement.

Scancell Holdings has announced that it will present clinical data from its ongoing Phase 2 SCOPE trial of the SCIB1 melanoma vaccine at the 2025 AACR Annual Meeting. The trial, which investigates the use of SCIB1 in combination with checkpoint inhibitors for late-stage melanoma, has shown promising results with an 84% disease control rate and 80% progression-free survival. These findings underscore the potential of SCIB1 to transform melanoma treatment and will guide the design of a future global randomized control registration trial.

More about Scancell Holdings

Scancell Holdings is a clinical stage biopharmaceutical company focused on developing novel immunotherapy products for cancer treatment. The company utilizes its proprietary research and technology platforms, including Moditope®, ImmunoBody®, GlyMab®, and AvidiMab®, to create innovative vaccines and antibodies that target specific modifications in proteins and lipids, addressing significant unmet needs in oncology.

YTD Price Performance: -26.51%

Average Trading Volume: 828,896

Technical Sentiment Signal: Buy

Current Market Cap: £81.91M

For an in-depth examination of SCLP stock, go to TipRanks’ Stock Analysis page.